#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Name Tech:

Kelly, Leslie

T. Zeman, CRT, RPsgT.

Doctor: G. Fino, M.D.

882590 ID: Height: 70.00


D.O.B.: 12/17/1962 44 Age:

Date: 01/16/2007 Room: Outpatient

Sex:

Male

Race: Black



### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000 Fax: 412-942-2024


Name	Kelly, Leslie	ID:	882590	D.O.B.	:12/17/1962	Date:	01/16/2007
Tech:	T. Zeman, CRT, RPsgT.	Height:	70.00	Age:	44	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	192.00	Sex:	Male	Race:	Black


Time	Select	I-Lp	Test Mode	ATS						
		-			FVC	FVC	FEV1	FEV1	FEV1/FVC	FEF 25-75%
					absolute	% p/c	absolute	% p/c	absolute	absolute
Pre										
10:53:29	*				4.10	95	3.38	97	82	3.91
10:52:26	*			back e	3.89	90	3.37	96	87	4.34
10:54:14	*			back e	3.93	91	3.28	94	84	3.60
Composite			Pre/Baseline		4.10	95	3.38	97	82	3.91


10:52:26

10:53:29

10:54:14







#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243


Phone: 412-942-2000

Fax: 412-942-2024

Name Kelly, Leslie
Tech: T. Zeman, CRT, RPsgT.
Doctor: G. Fino, M.D.

ID: 882590 Height: 70.00 D.O.B.: 12/17/1962 Age: 44 Date: 01/16/2007 Room: Outpatient

Weight: 192.00 Sex: Male Race: Black



## **Pulmonary Function Report**


1000 Bower Hill Rd. Pittsburgh, PA, 15243

Fax: 412-942-2024 Phone: 412-942-2000


Name Kelly, Leslie	ID:	882590	D.O.B.: 12/17/1962	Date:	01/16/2007
Tech: T. Zeman, CRT, RP	sgT Height:	70.00	Age: 44	Room:	Outpatient
Doctor: G. Fino, M.D.	Weight:	192.00	Sex: Male	Race:	Black

Time	Select	RpLp	Test Mode	Codes	Protocol					
						<b>DLCOunc</b>	DLCOund	DLCOcor 1	DLCOcor	DL/VA
		•				absolute	% p/c	absolute	% p/c	absolute
Predicted						37.99		37.35		5.58
Pre										
11:03:17				Inspirat	Jones-Mea	17.48	46			6.05
11:06:17	*				Jones-Mea	23.89	63			4.10
11:11:11	*				Jones-Mea	24.72	65			4.45
AVG			Pre/Baseline			24.31	64			4.27





#### 11:11:11



#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000


Fax: 412-942-2024

Name Kelly, Leslie
Tech: T. Zeman, CRT, RPsgT.
Doctor: G. Fino, M.D.

ID: 882590 Height: 70.00 Weight: 192.00 D.O.B.: 12/17/1962 Age: 44

Date: 01/16/2007 Room: Outpatient

Sex: Male Race: Black



### **Pulmonary Function Report**


1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone:	412-942-2000	Fax: 4	112-942-2024

Name	Kelly, Leslie	ID:	882590	D.O.B.	:12/17/1962	Date:	01/16/2007	
Tech:	T. Zeman, CRT, RPsgT.	Height:	70.00	Age:	44	Room:	Outpatient	
Doctor:	G. Fino, M.D.	Weight:	192.00	Sex:	Male	Race:	Black	

Time	Select	RpLp	Test Mode					
				FRC (N2) absolute	FRC (N2) % p/c	RV (N2) absolute	RV (N2) % p/c	TLC (N2)
Predicted				3.47	-	2.07	_	7.13
Pre								
11:16:22	*			4.95	143	3.47	168	7.65
AVG			Pre/Baseline	4.95	143	3.47	168	7.65





KELLY, LESLIE

MR#:882590 SEX:M AGE:44Y BIRTH:12/17/1962

DOCTOR: FINO, GREGORY J., M.D.

1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

ST CLAIR HOSPITAL LABORATORY

1000 BOWER HILL ROAD

PITTSBURGH, PA 15243

MARTHA R. CLARKE, MD, MEDICAL DIRECTOR

T5683 COLL: 01/16/2007 11:48 REC: 01/16/2007 11:51

COMP METABOLIC			
SGOT/AST	23	[0-50]	υ/L
SGPT/ALT	46	[0-50]	U/L
ALKALINE PHOSPHAT	72	[43-122]	U/L
BILIRUBIN TOTAL	0.5	[0.2-1.3]	MG/DL
PROTEIN		[6.0-8.4]	•
ALBUMIN	4.4	[3.5-5.0]	G/DL
CALCIUM	9.8	<del>_</del>	G/DL
GLUCOSE	77	[8.0-10.2] [70-110]	MG/DL
BUN	9	[8-25]	MG/DL
CREATININE	1.1	[0.6-1.5]	MG/DL
GFR (CAUCAS/OTHER)	>59		MG/DL
GFR (AFRICAN AMER)	>59	[>59]	ML/MIN
SODIUM	139	[>59]	ML/MIN
POTASSIUM	4.5	[133-145]	MMOL/L
CHLORIDE	104	[3.5-5.0]	MMOL/L
CO2	28	[96-108]	MMOL/L
ANION GAP		[22-30]	MMOL/L
ANION GAP	@ /	[8-16]	MMOL/L
CBC HEMOGRAM			
WBC	5.9	[4.8-10.8]	K/UL
RBC	5.71	[4.7-6.2]	M/UL
HEMOGLOBIN	15.9	[14.0-17.0]	GM/DL
HEMATOCRIT	46.4	[42.0-52.0]	8 G147 DTI
MCV	81.3	[78.0-94.0]	FL
MCH	27.8	[25.0-35.0]	PG
MCHC	34.3	[31.0-36.5]	G/DL
RDW	14.4	[12.9-14.9]	8 G\DTI
PLATELET	173	[130-460]	γ K/UL
MPV	9.6	[7.4-10.4]	FL
		[/.4-10.4]	ьт
DIFF, ELECTRONIC			
ABSOLUTE NEUTROPH	3.1	[1.5-6.6]	K/UL
ABSOLUTE LYMPHOCY	2.5	[1.5-3.5]	K/UL
ABSOLUTE MONOCYTE	0.2	[0-0.9]	K/UL
ABSOLUTE EOSINOPH	0.2	[0-0.6]	K/UL
ABSOLUTE BASOPHIL	0.0	[0-0.1]	K/UL
NEUTROPHIL	52.9	[40-75]	۶, OII
LYMPHOCYTE	39.4	[20-40]	용
MONOCYTE	4.1	[1-8]	્ર ક
EOSINOPHIL	2.8	[0-5]	ફ
BASOPHIL	0.8	[0-1]	e e
		1	•

#### PAGE:1

FINO, GREGORY J., M.D. 1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

\* = CRITICAL VALUE

1TIME

@ = OUTSIDE NORMAL RANGE

END OF REPORT

# CLINICAL & OCCUPATIONAL PULMONARY ASSOCIATES, LLC

Gregory J. Fino, MD, FCCP

St. Clair Hospital 1000 Bower Hill Road, Suite 211 Pittsburgh, Pennsylvania 15243-1899

Telephone (412) 942-2025 (412) 942-2032 Email gregory.fino@stclair.org

KELLY, LESLIE

DATE

PULSE OXIMETRY

ppm COHb

#### CLINICAL & OCCUPATIONAL PULMONARY ASSOCIATES, LLC

St. Clair Hospital 1000 Bower Hill Road, Suite 211 Pittsburgh, Pennsylvania 15243-1899

Gregory J. Fino, MD, FCCP

Telephone (412) 942-2025 Fax (412) 942-2032 Email gregory.fino@stclair.org

January 22, 2007

Michael C. Colville
Assistant U.S. Attorney
U.S. Department of Justice
U.S. Post Office & Courthouse
700 Grant Street
Suite 4000
Pittsburgh, PA 15219

RE: Kevin Siggers v. United States

C.A. No. 03-335E SSN: 294-80-1228 DOB: 8/22/70 OIME: 1/2/07

Dear Attorney Colville:

I examined Mr. Siggers on January 2, 2007.

#### **Patient Profile**

Mr. Siggers was born in 1970 and is 36 years old.

#### His medications included:

- 1. Albuterol inhaler used as needed; not used on the day of this evaluation; estimates that he has been on an inhaler for 2 years or so; he believes it helps "a little bit." He uses the inhaler for chest pain and shortness of breath.
- 2. Finishing up a course of antibiotics today (prescribed for a "head cold").

He smoked off and on between the mid 1980s and 2004. He estimates that he smoked for about 7 of those years. He sometimes smoked cigars and at other times he smoked cigarettes. He only smoked 3-4 cigarettes or cigars per day - sometimes less than that. He also used cannabis off and on until about 1990.

#### **Occupational History**

Mr. Siggers worked for Unicor from 1999 until December 20, 2006. He cut the Micore Board until he switched to another job in October of 2003. He said that the ventilation was not good and that he was offered a garden mask (paper) but not a respirator. When he moved to his new position, he was not exposed as much to the particle board; however, he still had daily exposure to it. The Micore board was removed from the facility at the end of 2004. Mr. Siggers stated that although he was also exposed to the Lokweld adhesive, he believes that the Micore board was the problem.

He was also exposed to wood dust.

Early on in his work, he complained of shortness of breath and episodes of a bloody nose. He had to walk up an incline to get to his living quarters, and he noted shortness of breath when doing so. He has been short of breath since 1999. He also complains of tightness in his chest which he describes as a fist in the center of his chest.

Since the Micore board was removed from Unicor (in 2004), he continues to have shortness of breath and a tightness in his chest. The tightness in the chest can occur at rest and with exertion.

He has a dry cough with little mucous production. He does wheeze.

He also complains of a rash. He had to have a skin abscess drained from the back of his neck and his forearm. He also complained of dry skin. He noted that when he was not around the Micore, he would not have much itching. However, he still complains of itching over his elbows. He has been treated with Benadryl for the itching.

He is also worried about developing silicosis down the road.

He has never been worked up for heart disease.

## Past Medical History

- 1. Right hip replacement in 1984 - due to football injury; he had broken his pelvic socket bone
- 2. Hospitalized for pneumonia in the mid 1970s

Page 3

SIGGEK.DOJ

- 3. Nurse's assistant at the prison diagnosed asthma in 2003 or 2004
- 4. He estimates 2 to 3 head colds per year
- 5. See above notes re: skin abscess

He has no history of tuberculosis, emphysema, bronchitis or bronchiectasis. There is no history of fractured ribs.

#### Family History

There is no family history of lung disease or malignancy. There is a family history of diabetes (paternal grandfather, father and brother). There is also a family history of high blood pressure (paternal grandfather, father and brother).

#### **Review of Systems**

Neurologic:

No headaches or seizures

HEENT:

No chronic sinus problems

GI:

No history of chronic gastrointestinal disease

GU:

No chronic genitourinary problems

Endocrine:

No diabetes or thyroid disease

#### **Physical Examination**

General:

Well-developed, well-nourished African American

man in no acute distress, oriented X 3

Heart Rate:

70

Blood Pressure:

145/82

Respiratory Rate:

16

Height:

71" without shoes

Page 4

Weight:

264 lbs without shoes

Skin/Nails:

No cyanosis, clubbing, or edema

Neck:

Supple with a midline trachea; no thyromegaly

HEENT:

Unremarkable

Lungs:

Clear to auscultation and percussion on a tidal volume

breath and a forced expiratory maneuver without

wheezes, rales, rhonchi, or rubs

Heart:

Normal S1 and S2 without murmurs, gallops, or rubs

Abdomen:

No organomegaly

Peripheral Pulses:

2+ and equal

Extremities:

Negative

Edema:

Negative

Neurological Exam:

Intact

## Chest X-Ray

A two-view chest x-ray was performed in conjunction with this examination. The chest x-rays were compared to the revised 2000 ILO classification films.

I have also received for review the following radiographic studies, and I have compared all of the chest x-rays to the revised 2000 ILO classification films:

- 1. A Quality 1 PA film dated 7/23/03 performed at an unspecified facility.
- 2. A Quality 1 PA film dated 12/30/03 also performed at an unspecified facility.

Page 5

SIGGEK.DOJ

There were no pleural and no parenchymal abnormalities consistent with an occupationally acquired pneumoconiosis, and I classified all of the above-referenced chest x-rays as 0/0.

#### **Pulmonary Function Testing**

The American Thoracic Society, in conjunction with the European Respiratory Society, has published a follow-up article to their 1991 article on selection of reference values and interpretative strategies in pulmonary function testing.

The original 1991 article is entitled <u>Lung Function Testing</u>: <u>Selection of Reference</u>
<u>Values And Interpretative Strategies</u> (AM REV RESPIR DIS 1991; 144:1202-1218). The more recent article is entitled <u>Interpretative Strategies for Lung Function Tests</u> (EUR RESPIR J 2005; 26:948-968).

The following consensus recommendations have been issued in the 2005 consensus statement:

- ✓ If the patient's age or height is outside the limits of the reference population, a statement in the interpretation should indicate that an extrapolation has been made.
- The practice of using 80% as a fixed value for the lower limit of normal can lead to important errors when interpreting lung function in adults. The practice of using 0.70 as a lower limit of the FEV1/FVC ratio results in a significant number of false positive results in males aged greater than 40 years and females greater than 50 years, as well as in a risk of over diagnosis of chronic obstructive pulmonary disease in asymptomatic elderly never smokers.
- ✓ Volume corrections should be made for African-Americans and Hispanics when measuring spirometry. Values for lung volumes are, on average, 12% lower in African-Americans than in Caucasians.
- Recommended spirometric reference equations come from the National Health and Nutrition Examination Survey (NHANES III) published in 1999 (AM J RESPIR CRIT CARE MED 1999; 159:179-187).
- Recommended lung volume reference equations were published in 1995 (EUR RESPIR J 1995; 8:492-506).

Page 6

SIGGEK DOJ

A single set of diffusing capacity reference values could not be recommended. There were two commonly used equations referenced, one of which has been utilized since its publication in 1981 (AM REV RESPIR DIS; 123:185-189).

The earlier consensus statement also recommended abandoning the 80% cut off as normal and the 70% cut off for the FEV1/FVC. The new 2005 statement paper goes one step further and has recommended utilization of one set of reference equations for spirometry, one for lung volumes and then one of two for the diffusing capacity. Having reviewed these new recommendations and having reviewed the source material, I believe that it is medically reasonable to follow the recommendations in the statement papers.

I have included with the pulmonary function studies that are performed in conjunction with my examinations a new summary for the spirometry, lung volumes and diffusing capacity. This summary utilizes the above noted recommendations for the spirometry, lung volume and diffusing capacity reference equations.

#### **Spirometry**

The spirometry was invalid because of a premature termination to exhalation and a lack of reproducibility in the expiratory tracings. There was also a lack of an abrupt onset to exhalation. The values recorded for this spirometry represent at least the minimal lung function that this man could perform and certainly not this man's maximum lung function. (References: (1) Standardization of Spirometry. A.R.R.D. 1987; 136:1285-1298. (2) ATS Statement-Snowbird Workshop on Standardization of Spirometry. A.R.R.D. 1979; 119:831-838. (3) Statement on Spirometry. Chest 1983; 83:547-550. (4) ATS/ERS Task Force: Standardization of Lung Function Testing - Standardization of Spirometry. Eur Respir J 2005; 26: 319-338.)

## Lung Volumes

The residual volume was increased. Other than that, this study was normal.

## **Diffusing Capacity**

The diffusing capacity was invalid because the inspiratory vital capacity was less than 90% of the forced vital capacity. However, when taking into consideration alveolar volume, the diffusing capacity was normal.

Page 7

SIGGEK.DOJ

#### Oxygen Saturation

Normal

#### Carboxyhemoglobin Level

Normal

#### **Laboratory Results**

Complete blood count, liver panel and renal function were all normal.

#### Medical Record Review

In conjunction with this evaluation, I also reviewed the following information:

- 1. Background information which included:
  - The Microbac Indoor Airy Quality Survey dated 7/31/01.
  - The Declaration of Michael Salerno, dated 1/19/05, with detailed information regarding the ventilation system.
  - The McKean time line, which identified when and where the Plaintiff worked within the UNICOR Factory.
  - Material Safety Data Sheets for Micore Board
  - The OSHA Inspection Report and supporting documentation.

Micore Board is a man-made product which contains man-made vitreous fiber, expanded perlite, starch, recycled paper, kaolin and crystalline silica.

Lokweld is a sprayed grade adhesive used for laminate. It contains acetone, toluene, hexane isomers, and N-hexane.

Page 8

In a letter dated August 20, 2003, Mr. Stranahan (from OSHA) discussed the air monitoring results that had been taken to evaluate the workers' exposure to concentrations of airborne dust. In this letter he stated that the "results showed no worker's exposure exceeded 10% of the relevant exposure limit." He also recommended a number of steps that could be voluntarily taken to eliminate and/or further reduce the workers' exposure to dust. OSHA found no evidence of first marble silica.

- 2. A copy of the Amended Complaint.
- 3. The Declarations of Debora Forsyth, Assistant Warden, dated 7/27/04 and 1/30/06.
- 4. The Declaration of Joyce Horikawa, Senior Attorney Advisor, dated 7/30/04.
- 5. The Declarations of Martin Sapko, Factory Manager, dated 7/30/04 and 1/25/06.
- 6. The Declaration of Dennis Olson, M.D., dated 7/30/04, including his summary of the Plaintiff's medical attention at FCI McKean.
- 7. A true and correct copy of the Plaintiff's medical records attached to Dr. Olson's Declaration of 7/30/04.
- 8. The Declaration of Stephen Housler, Safety Manager, dated 1/25/06.
- 9. A transcript of the video conference deposition of Mr. Siggers dated 10/31/06.
- 10. In addition to the information noted above, I also had an opportunity to review miscellaneous records on CD ROMS that accompanied the files forwarded to my office.

## **Diagnosis**

Normal Pulmonary Examination

Kevin Siggers
January 22, 2007
Page 9

SIGGEK.DOJ

#### **Discussion**

I find no evidence of a respiratory impairment or disability. This man's spirometry was invalid; his diffusing capacity was also invalid, but it was normal when taking into consideration alveolar volume.

The determination of pulmonary impairment and subsequent disability has been extensively researched in the American medical literature. In the late 1980s, there was a worldwide conference on the assessment of respiratory impairment sponsored by the National Institutes of Health. This was published in the American Review of Respiratory Disease in 1988 (ARRD 1988; 137:1505-1510). All of the participants agreed that symptoms of shortness of breath on effort and exercise intolerance were not reliable predictors of impairment. There was also agreement that a physical examination was not helpful in measuring pulmonary impairment. Lung function tests, however, were essential in assessing whether or not impairment was present and essential in rating its severity. Dr. Hans Weill commented that "resting lung function tests, usually spirometry, all are the cornerstone in the clinician's assessment of respiratory impairment, and provided they are technically sound, are generally believed to be adequate for ascertaining the presence of respiratory limitation. Likewise, it is generally believed that exercise limitation is not likely to be present in the face of normal or marginal resting lung function."

Similar statements have been issued by the American Thoracic Society and the American Medical Association with respect to guidelines for the evaluation of respiratory impairment. It is of utmost importance that valid lung function studies be performed. An invalid study does not represent the patient's maximum pulmonary capacity and cannot be used to assess impairment or disability. An invalid pulmonary function study indicates poor patient effort. The values recorded can only represent the minimum lung function of the patient.

According to his history, Mr. Siggers is still quite active. If indeed this man really had the lung function that was depicted in the invalid spirometry, he would not be able to be that active.

There is no evidence of either chronic or accelerated silicosis based on the normal chest films.

Page 10

SIGGEK.DOJ

This patient should have no fear of contracting silicosis in the future. First of all, there were no measurable levels of respirable silica noted by OSHA. Furthermore, it is well documented in the medical literature that at least 20 years of exposure to dust that is measurable and above the PEL is required before chronic silicosis occurs.

If Mr. Siggers were my patient, I would not follow him for the subsequent development of silicosis, and I would assure him that he has no reason to worry about developing silicosis in the future.

I find no evidence of any chronic condition with reference to his eyes or throat or skin.

This patient has been diagnosed with asthma. As I reviewed the medical records, I found no evidence to support that diagnosis. That is based on the lack of findings of wheezing as well as a lack of any lung function studies that showed changes consistent with asthma. I would note that, at times, there were measurements of peak flow. However, those are unacceptable in this case because I have no idea whether this man gave a good effort. Suffice it to state that there is no objective evidence of an asthmatic condition.

#### **Conclusions**

My conclusions have been reached with a reasonable degree of medical certainly. I find no evidence of any chronic condition of the lungs or pulmonary system related to his alleged exposures. I find no evidence of a chronic condition with reference to the skin, eyes or nose.

Sincerely,

Gregory J. Fino, M.D., F.C.C.P.

GJF/kms

#### CLINICAL AND OCCUPATIONAL PULMONARY ASSOCIATES

GREGORY J. FINO, M.D., F.C.C.P.

## PREDICTED VALUES BASED ON THE 2005 SPIROMETRY RECOMMENDATIONS Recommendations from the ATS/ERS: INTERPRETATIVE STRATEGIES FOR LUNG FUNCTION TESTS EUR RESPIR J 2005; 26:948-968.

Name	Siggers, Kevin		MD	Fino	
Ht	180.3	cm	Date	1/2/2007	
Age	36	years	Race	African American	

#### SPIROMETRY PREDICTED VALUES USING THE NHANES HI STUDY

Spirometric Reference Values from a Sample of the General U.S. Population AM J RESPIR CRIT CARE MED 1999; 159:179-187

TEST	PATIENT	PRED	%PRED	LLN	IAN%
FVC	3.12	4.60	68	3.64	79
FEV1	2.15	3.80	57	2.94	77
FEV1/FV0	69	83		72	
FEF25-75	1.88	4.02	47.	2.19	54

REFERENCE VALUES FOR RV,FRC AND TLC - ATS WORKSHOP ON LUNG VOLUME MEASUREMENTS OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY EUR RESPIR J 1995; 8:492-506

L.V.	PATIENT	PRED	%PRED	LLN	LLN%	ULN	ULN%	
TLC	5.32	6.45	83	5.24	81	8.70	135	
RV	2.38	1.69	141	1.10	65	2.59	153	
FRC	2.94	3.07	96	2.20	72	4.48	146	
RV/TLC%	45	28	160	17	62	39	138	

#### STANDARDIZED SINGLE BREATH NORMAL VALUES FOR THE DLCO AM REV RESPIR DIS 1981:123:185-189

DLCO	PATIENT	PRED	%PRED	LLN	LLN%	
DLCO	26.12	35.89	73	28.67	80	
DL/VA	6.00	5.15	116	3.92	76	

Prebronchodilator

**FVC** FEV1 FEV1/FVC

**Post Bronchodilator** 

FVC -FEV1

FEF25-75

**Lung Volumes** 

FRC \ RV/TLC **Diffusing Capacity** 

DL/VA N **IMPRESSION** 

PR	E		
FVC	3.12		
FEV1	2.15		
FEVL/FVC	69		
FEF25-75	1.88	PR	E
TLC	5.32	RV/TLC%	45
RV	2.38	DLCO	26.12
FRC	2.94	DL/VA	6

Gregory J. Fino, M.D.

### **Pulmonary Function Report**

1000 Bower Hill Rd.

Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Name	Siggers, Kevin	ID:	88-19-57	D.O.B.	:08/22/1970	Date:	01/02/2007
Tech:	Bozic, J. RRT	Height:	71.00	Age:	36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	264.00	Sex:	Male	Race:	Black

Diagnosis: SOB

Dyspnea: After any exertion

Cough: Non-Productive

Wheeze: No Wheeze

Tbco Prod: Cigarette

Yrs Smk: 7.0

3.0 Pks/Day:

Yrs Quit:

2.0

Medications:

**Pre Test Comments:** 

Post Test Comments:

Patient met ATS standards. PFT Authors DLCO (Crapo), FVC (Nhanes III), FRC

(ECCS)

	Pre	-Bronch		Po	st-Bronch	
	<u>Actual</u>	<u>Pred</u>	%Pred	<u>Actual</u>	%Pred	%Chng
SPIROMETRY						
FVC (L)	3.12	4.61	68			
FEV1 (L)	2.15	3.80	57	•		
FEV1/FVC (%)	69	83	83			
FEF 25% (L/sec)	2.27	9.09	25			
FEF 75% (L/sec)	1.06	2.20	48			
FEF 25-75% (L/sec)	1.88	4.02	47			
FEF Max (L/sec)	2.56	9.65	27			
FIVC (L)	2.47					
FIF Max (L/sec)	1.80					
LUNG VOLUMES	•			•		
SVC (L)	2.94	5.32	55			
IC (L)	2.38	3.57	67			
ERV (L)	0.56	1.75	32			
FRC (N2) (L)	2.94	3.45	85			
RV (N2) (L)	2.38	1.92	124			
TLC (N2) (L)	5.32	7.33	73			•
RV/TLC (N2) (%)	45	28	160			
Washout Time (min)	2.12					
•						
DIFFUSION				•		
DLCOunc (ml/min/mmHg)	26.12	40.80	64			
DLCOcor (ml/min/mmHg)		40.80				
DL/VA (ml/min/mmHg/L)	6.00	5.86	102			
VA(L)	4.36	7.12	61			
IVC (L)	2.48					
BHT (sec)						

## **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024


Siggers, Kevin Name Bozic, J. RRT Tech: Doctor: G. Fino, M.D.


D: 88-19-57 Height: 71.00

D.O.B.:08/22/1970 Age: 36

01/02/2007 Date: Room: Outpatient

Male





## **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024


) T	C'	ID.	88-19-57	DOD	:08/22/1970	Doto	01/02/2007
Name:	Siggers, Kevin	ID:	00-19-37	D.U.D.	00/22/19/0	Date.	01/02/2007
Tech:	Bozic, J. RRT	Height:	71.00	Age:	36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	264.00	Sex:	Male	Race:	Black


Time	Select	I-Lp	Test Mode	ATS							
		_			FVC	FVC				FEF 25-75%	
					absolute	% p/c	absolute	% p/c	absolute	absolute	
Pre				-							
11:18:23	*				3.12	68	2.15	57	69	1.88	
11:16:41	*				3.06	66	1.99	52	65	1.54	
11:13:52	*				2.82	61	2.09	55	74	1.93	
ATS			Pre/Baseline		3.12	68	2.15	57	69	1.88	


11:13:52

11:16:41

11:18:23







#### **Pulmonary Function Report**


1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Name: Siggers, Kevin Tech: Bozic, J. RRT Doctor: G. Fino, M.D. ID: 88-19-57 Height: 71.00 D.O.B.: 08/22/1970 Age: 36 Date: 01/02/2007 Room: Outpatient

Weight: 264.00 Sex: Male Race: Black



### **Pulmonary Function Report**


1000 Bower Hill Rd. Pittsburgh, PA, 15243


Phone: 412-942-2000


Fax: 412-942-2024

Name	Siggers, Kevin	ID:	88-19-57	D.O.B.	.:08/22/1970	Date:	01/02/2007
Tech:	Bozic, J. RRT	Height:	71.00	Age:	36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	264.00	Sex:	Male	Race:	•

Time	Select	RpLp	Test Mode	Codes	Protocol					
						<b>DLCOunc</b>	DLCOunc	DLCOcor	DLCOcor	DL/VA
						absolute	% p/c	absolute	% p/c	absolute
Predicted						40.80		40.80	_	5.86
Pre										
11:26:14	*				Jones-Mea	27.72	68			5.63
11:31:06				Inspirat	Jones-Mea	24.43	60			6.23
11:35:45	*			Inspirat	Jones-Mea	26.06	64			6.88
11:40:33	*			•	Jones-Mea	24.60	60			5.65
AVG		]	Pre/Baseline			26.12	64			6.00







#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024


Siggers, Kevin Name: Tech: Bozic, J. RRT Doctor: G. Fino, M.D.


ID: 88-19-57

D.O.B.: 08/22/1970 36

01/02/2007 Date: Room: Outpatient

Height: 71.00 Age: Weight: 264.00 Sex: Male Black Race:





#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Name:	Siggers, Kevin
Tech:	Bozic, J. RRT
Doctor:	G. Fino, M.D.


ID: 88-19-57 Height: 71.00 Weight: 264.00 D.O.B.: 08/22/1970 Age: 36

Male

Sex:

Date: 01/02/2007 Room: Outpatient Race: Black

	·						
Time	Select	RpLp Test Mode			DV (NO)		
				FRC (N2)			TLC (N2)
			absolute	% p/c	absolute	% p/c	absolute
Predicted			3.45		1.92		7.33
Pre							¢
11:46:12	*						
11:47:19	*						
11:51:33	*		2.94	85	2.38	124	5.32
4370		D /D 1'	0.04	0.5	2.20	104	£ 20



SIGGERS, KEVIN

MR#:881957 SEX:M AGE:36Y BIRTH:08/22/1970

DOCTOR: FINO, GREGORY J., M.D.

1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

ST CLAIR HOSPITAL LABORATORY

1000 BOWER HILL ROAD

PITTSBURGH, PA 15243

MARTHA R. CLARKE, MD, MEDICAL DIRECTOR

T9258 COLL: 01/02/2007 10:14 REC: 01/02/2007 10:16

COMP METABOLIC			
SGOT/AST	33	[0-50]	U/L
SGPT/ALT	26	[0-50]	U/L
ALKALINE PHOSPHAT	67	[43-122]	U/L
BILIRUBIN TOTAL	0.7	[0.2-1.3]	MG/DL
PROTEIN	7.9	[6.0-8.4]	G/DL
ALBUMIN	4.2	[3.5-5.0]	G/DL
CALCIUM	9.1	[8.0-10.2]	MG/DL
GLUCOSE	109	[70-110]	MG/DL
BUN	11	[8-25]	MG/DL MG/DL
CREATININE	1.1	[0.6-1.5]	MG/DL
GFR (CAUCAS/OTHER)	>59	[>59]	ML/MIN
GFR (AFRICAN AMER)	>59	[>59]	ML/MIN
SODIUM	136	[133-145]	MMOL/L
POTASSIUM	3.9	[3.5-5.0]	MMOL/L
CHLORIDE	100	[96-108]	MMOL/L
CO2	29	[22-30]	MMOL/L
ANION GAP	@7	[8-16]	MMOL/L
CBC HEMOGRAM		•	
WBC	6.9	[4.8-10.8]	K/UL
RBC	4.82	[4.7-6.2]	M/UL
HEMOGLOBIN	14.6	[14.0-17.0]	GM/DL
HEMATOCRIT	@40.6	[42.0-52.0]	ક
MCV	84.2	[78.0-94.0]	FL
MCH	30.3	[25.0-35.0]	PG
MCHC	36.0	[31.0-36.5]	G/DL
RDW	13.3	[12.9-14.9]	ક
PLATELET	286	[130-460]	K/UL
MPV	8.1	[7.4-10.4]	FL
DIFF, ELECTRONIC			
ABSOLUTE NEUTROPH	4.3	[1.5-6.6]	K/UL
ABSOLUTE LYMPHOCY	2.0	[1.5-3.5]	K/UL
ABSOLUTE MONOCYTE	0.3	[0-0.9]	K/UL
ABSOLUTE EOSINOPH	0.4	[0-0.6]	K/UL
ABSOLUTE BASOPHIL	0.1	[0-0.1]	K/UL
NEUTROPHIL	62.2	[40-75]	왕
LYMPHOCYTE	26.7	[20-40]	e ·
MONOCYTE	4.2	[1-8]	.8
	@6.1	[0-5]	왕
BASOPHIL	0.9	[0-1]	용

PAGE:1

FINO, GREGORY J., M.D. 1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

1TIME

\* = CRITICAL VALUE

@ = OUTSIDE NORMAL RANGE

END OF REPORT

# CLINICAL & OCCUPATIONAL PULMONARY ASSOCIATES, LLC

Gregory J. Fino, MD, FCCP

St. Clair Hospital 1000 Bower Hill Road, Suite 211 Pittsburgh, Pennsylvania 15243-1899

Telephone (412) 942-2025 Fax (412) 942-2032 Email gregory.fino@stclair.org

PATIENT <u>SIGGERS, KEVIN</u>

PULSE OXIMETRY

100/ RA

CC = 1 ppm

<u>О</u> Z сонь

#### CLINICAL & OCCUPATIONAL PULMONARY ASSOCIATES, LLC

St. Clair Hospital

1000 Bower Hill Road, Suite 211 Pittsburgh, Pennsylvania 15243-1899

Gregory J. Fino, MD, FCCP

Telephone (412) 942-2025 Fax (412) 942-2032 Email gregory.fino@stclair.org

January 22, 2007

Michael C. Colville
Assistant U.S. Attorney
U.S. Department of Justice
U.S. Post Office & Courthouse
700 Grant Street
Suite 4000
Pittsburgh, PA 15219

**RE:** Myron Ward v. United States

C.A. No. 04-11E SSN: 579-96-8834

**DOB:** 7/7/70 **OIME:** 1/8/07

Dear Attorney Colville:

I examined Mr. Ward on January 8, 2007.

#### Patient Profile

Mr. Ward was born in 1970 and was 36 years old. His only medication was Nasonex - for chronic sinusitis. He has never used inhalers for his lungs.

He never smoked.

## **Occupational History**

Mr. Ward worked at Unicor from April of 2002 until October of 2003. He helped with the cutting of the Micore board and was exposed to a lot of dust. He was also exposed to the dust from cutting particle board, and fumes from a glue used for the laminate - Lokweld. He was provided paper masks, but he only "sometimes" used them.

Page 2

WARDM.DOJ

He denied any breathing problems prior to working at Unicor. He noticed breathing problems after he had been working there for about 6 months. He started to notice nasal congestion at night and a runny nose during the day. He also noted coughing at night when he would lie down. He had headaches and developed some conjunctivitis as well as episcleritis. He noted pruritis of the chest and the back.

Since he stopped working, the skin complaints are gone. He still has the coughing at night time and the chronic sinusitis.

He also stated that he can no longer run, and he has shortness of breath. He used to run 3 miles per day, but now he has to run a little bit - and then walk.

#### **Past Medical History**

- 1. Biopsy of lump on right side of neck not cancerous
- 2. History of sinus problems; has had rhinitis
- 3. History of hemorrhoids

He has no history of pneumonia, tuberculosis, emphysema, asthma, bronchitis, bronchiectasis, or frequent colds. There is no history of fractured ribs.

#### **Family History**

There is no family history of lung disease. His paternal grandmother had a history of cancer. There is also a family history of heart problems (father died of a heart attack).

## **Review of Systems**

Neurologic:

No headaches or seizures

GI:

No history of chronic gastrointestinal disease

CVS:

No history of cardiovascular disease

MS:

No chronic musculoskeletal problems

Endocrine:

No diabetes or thyroid disease

Page 3

WARDM.DOJ

#### **Physical Examination**

General:

Well-developed, well-nourished Black man in no acute

distress, oriented X 3

Heart Rate:

66

Blood Pressure:

136/68

Respiratory Rate:

14

Height:

68" without shoes

Weight:

150.6 lbs without shoes

Skin/Nails:

No cyanosis, clubbing, or edema

Neck:

Supple with a midline trachea; no thyromegaly

HEENT:

Unremarkable

Lungs:

Clear to auscultation and percussion on a tidal volume

breath and a forced expiratory maneuver without

wheezes, rales, rhonchi, or rubs

Heart:

Normal S1 and S2 without murmurs, gallops, or rubs

Abdomen:

No organomegaly

Peripheral Pulses:

2+ and equal

Extremities:

Negative

Edema:

Negative

Neurological Exam:

Intact

Page 4

WARDM.DOJ

#### Chest X-Ray

A two-view chest x-ray was performed in conjunction with this examination. The chest x-rays were compared to the revised 2000 ILO classification films.

There were no pleural and no parenchymal abnormalities consistent with an occupationally acquired pneumoconiosis.

Classification:

0/0

#### **Pulmonary Function Testing**

The American Thoracic Society, in conjunction with the European Respiratory Society, has published a follow-up article to their 1991 article on selection of reference values and interpretative strategies in pulmonary function testing.

The original 1991 article is entitled <u>Lung Function Testing</u>: <u>Selection of Reference</u>
<u>Values And Interpretative Strategies</u> (AM REV RESPIR DIS 1991; 144:1202-1218). The more recent article is entitled <u>Interpretative Strategies for Lung Function Tests</u> (EUR RESPIR J 2005; 26:948-968).

The following consensus recommendations have been issued in the 2005 consensus statement:

- ✓ If the patient's age or height is outside the limits of the reference population, a statement in the interpretation should indicate that an extrapolation has been made.
- The practice of using 80% as a fixed value for the lower limit of normal can lead to important errors when interpreting lung function in adults. The practice of using 0.70 as a lower limit of the FEV1/FVC ratio results in a significant number of false positive results in males aged greater than 40 years and females greater than 50 years, as well as in a risk of over diagnosis of chronic obstructive pulmonary disease in asymptomatic elderly never smokers.
- ✓ Volume corrections should be made for African-Americans and Hispanics when measuring spirometry. Values for lung volumes are, on average, 12% lower in African-Americans than in Caucasians.

Page 5

WARDM.DOJ

- Recommended spirometric reference equations come from the National Health and Nutrition Examination Survey (NHANES III) published in 1999 (AM J RESPIR CRIT CARE MED 1999; 159:179-187).
- Recommended lung volume reference equations were published in 1995 (EUR RESPIR J 1995; 8:492-506).
- A single set of diffusing capacity reference values could not be recommended. There were two commonly used equations referenced, one of which has been utilized since its publication in 1981 (AM REV RESPIR DIS; 123:185-189).

The earlier consensus statement also recommended abandoning the 80% cut off as normal and the 70% cut off for the FEV1/FVC. The new 2005 statement paper goes one step further and has recommended utilization of one set of reference equations for spirometry, one for lung volumes and then one of two for the diffusing capacity. Having reviewed these new recommendations and having reviewed the source material, I believe that it is medically reasonable to follow the recommendations in the statement papers.

I have included with the pulmonary function studies that are performed in conjunction with my examinations a new summary for the spirometry, lung volumes and diffusing capacity. This summary utilizes the above noted recommendations for the spirometry, lung volume and diffusing capacity reference equations.

## **Spirometry**

The spirometry was invalid because of a premature termination to exhalation and a lack of reproducibility in the expiratory tracings. There was also a lack of an abrupt onset to exhalation. The values recorded for this spirometry represent at least the minimal lung function that this man could perform and certainly not this man's maximum lung function. (References: (1) Standardization of Spirometry. A.R.R.D. 1987; 136:1285-1298. (2) ATS Statement-Snowbird Workshop on Standardization of Spirometry. A.R.R.D. 1979; 119:831-838. (3) Statement on Spirometry. Chest 1983; 83:547-550. (4) ATS/ERS Task Force: Standardization of Lung Function Testing - Standardization of Spirometry. Eur Respir J 2005; 26: 319-338.)

## Lung Volumes

The lung volumes were invalid.

Page 6

WARDM.DOJ

#### **Diffusing Capacity**

Eight attempts were made, but none were acceptable.

#### Oxygen Saturation

Normal

## Carboxyhemoglobin Level

Normal

#### **Laboratory Results**

Liver function and renal function studies were normal, as was his complete blood count.

#### Medical Record Review

In conjunction with this evaluation, I reviewed the following information:

- 1. Background information which included:
  - The Microbac Indoor Airy Quality Survey dated 7/31/01.
  - The Declaration of Michael Salerno, dated 1/19/05, with detailed information regarding the ventilation system.
  - The McKean timeline, which identified when and where the Plaintiff worked within the UNICOR Factory.
  - Material Safety Data Sheets for Micore Board and Lokweld.
  - The OSHA Inspection Report and supporting documentation.

Micore Board is a man-made product which contains man-made vitreous fiber, expanded perlite, starch, recycled paper, kaolin and crystalline silica.

Page 7

WARDM.DQJ

Lokweld is a sprayed grade adhesive used for laminate. It contains acetone, toluene, hexane isomers, and N-hexane.

In a letter dated August 20, 2003, Mr. Stranahan (from OSHA) discussed the results of air monitoring to evaluate worker exposures to airborne dust concentrations. He stated that the "results showed no worker's exposure exceeded 10% of the relevant exposure limit." He did recommend a number of steps that could be voluntarily taken to eliminate or further reduce the workers' exposure to dust. No respirable silica was found.

- 2. A copy of the Second Amended Complaint.
- 3. The Declaration of Ned Watson, Correctional Counselor, dated 7/7/04.
- The Plaintiff's Affidavit dated 6/17/05. 4.
- The Declaration of Stephen Housler, Safety Manager, dated 1/25/06. 5.
- 6. The Declaration of Martin Sapko, Factory Manager, dated 1/25/06.
- The Declaration of Debora Forsyth, Associate Warden, dated 1/30/06. 7.
- The Declaration of Douglas Goldring, Assistant General Counsel, dated 1/30/06. 8.
- 9. A true and correct copy of the Plaintiff's medical records attached to Mr. Goldring's Declaration of 1/30/06.
- 10. The deposition transcript of Myron Ward dated 11/1/06.
- In addition to the information noted above, I also had an opportunity to review 11. miscellaneous records on CD ROMS that accompanied the files forwarded to my office.

## **Diagnosis**

Normal Pulmonary Examination

Page 8

WARDM.DOJ

#### **Discussion**

I find no evidence of a respiratory impairment or disability. This man's spirometry and lung volumes were both invalid.

The determination of pulmonary impairment and subsequent disability has been extensively researched in the American medical literature. In the late 1980s, there was a worldwide conference on the assessment of respiratory impairment sponsored by the National Institutes of Health. This was published in the American Review of Respiratory Disease in 1988 (ARRD 1988; 137:1505-1510). All of the participants agreed that symptoms of shortness of breath on effort and exercise intolerance were not reliable predictors of impairment. There was also agreement that a physical examination was not helpful in measuring pulmonary impairment. Lung function tests, however, were essential in assessing whether or not impairment was present and essential in rating its severity. Dr. Hans Weill commented that "resting lung function tests, usually spirometry, all are the cornerstone in the clinician's assessment of respiratory impairment, and provided they are technically sound, are generally believed to be adequate for ascertaining the presence of respiratory limitation. Likewise, it is generally believed that exercise limitation is not likely to be present in the face of normal or marginal resting lung function."

Similar statements have been issued by the American Thoracic Society and the American Medical Association with respect to guidelines for the evaluation of respiratory impairment. It is of utmost importance that valid lung function studies be performed. An invalid study does not represent the patient's maximum pulmonary capacity and cannot be used to assess impairment or disability. An invalid pulmonary function study indicates poor patient effort. The values recorded can only represent the minimum lung function of the patient.

There is no evidence of either chronic or accelerated silicosis based on the normal chest films.

This patient should have no fear of contracting silicosis in the future. First of all, there were no measurable levels of respirable silica noted by OSHA. Furthermore, it is well documented in the medical literature that at least 20 years of exposure to dust that is measurable and above the PEL is required before chronic silicosis occurs.

Page 9

If Mr. Ward were my patient, I would not follow him for the subsequent development of silicosis, and I would assure him that he has no reason to worry about developing silicosis in the future.

I find no evidence of any chronic condition with reference to his eyes or throat or skin.

#### **Conclusions**

My conclusions have been reached with a reasonable degree of medical certainly. I find no evidence of any chronic condition of the lungs or pulmonary system related to Mr. Ward's alleged exposures. I find no evidence of a chronic condition with reference to the skin, eyes or nose.

Sincerely,

Gregory J. Fino, M.D., F.C.C.P.

GJF/kms

## CLINICAL AND OCCUPATIONAL PULMONARY ASSOCIATES

-GREGORY J. FINO, M.D., F.C.C.P.

## PREDICTED VALUES BASED ON THE 2005 SPIROMETRY RECOMMENDATIONS Recommendations from the ATS/ERS: INTERPRETATIVE STRATEGIES FOR LUNG FUNCTION TESTS EUR RESPIR J 2005; 26:948-968.

Name	Ward,	Myron	MD	Fino	
H	172.7	cm	Date	1/8/2007	
Age	36	years	Race	African American	

## SPIROMETRY PREDICTED VALUES USING THE NHANES III STUDY

Spirometric Reference Values from a Sample of the General U.S. Population

AM J RESPIR CRIT CARE MED 1999; 159:179-187

e e e e e e	PATIENT	PRED	%PRED	LLN	LLN%	POST	%PRED	BD %	
TEST FVC	3.08	4.16	74	3.27	79	4.11	99	33	
	3.00								
FEV1	1.11	3.45	32	2.66	77	2.42	70	118	
					naniamanaiina				
FEV1/FVC	36	83		72		59			
		<u>.</u>			<u> </u>			400	
FEF25-75	0.43	3.74	11	2.06	55	2.15	57	400	

## REFERENCE VALUES FOR RV,FRC AND TLC - ATS WORKSHOP ON LUNG VOLUME MEASUREMENTS OFFICIAL STATEMENT OF THE EUROPEAN RESPIRATORY SOCIETY

EUR RESPIR J 1995: 8:492-506

				<del>(( 0 1//0 ) 0</del>	and the same of th	nneneeneeneeneeneeneeneeneeneeneeneenee	\$5000000000000000000000000000000000000	
T.V.	PATIENT	PRED	%PRED	LLN	LLN%	ULN	ULN%	
TLC	9.74	5.91	165	4.71	80	8.09	137	
RV	8.15	1.61	508	1.02	63	2.49	155	
FRC	8.72	2.91	299	2.04	70	4.30	148	
RV/TLC%		28	300	17	62	39	138	

Prebronchodilator

MVALID

FVC

FEV1

FEV1/FVC

FEF25-75

Post Bronchodilator

**FVC** 

FEV1

Lung Volumes

INVALID

FRC

TLC

RV

RV/TLC

Gregory J. Fino, M.D.

PR	Œ	POS	T
FVC	3.08	FVC	4.11
FEV1	1.11	FEV1	2.42
FEV1/FVC	36	FER25-75	2.15
FEF25-75	0.43	PR	E
TLC	9.74	RV/TLC%	84
RV	8.15		
FRC	8.72		

#### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Name	Ward, Myron	ID:	881985	D.O.B.:07/07/1970	Date:	01/08/2007
	T. Zeman, CRT, RPsgT.	Height:	68.00	Age: 36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	150.60	Sex: Male	Race:	Black

Diagnosis: SOB

Dyspnea: After severe exertion

Cough: Non-Productive

Wheeze: No Wheeze

Tbco Prod: Never Smoked

Yrs Smk:

Pks/Day:

Yrs Quit:

Medications:

Pre Test Comments:
Post Test Comments:

PFT Authors DLCO (Crapo), FVC (Nhanes III), FRC (ECCS). Albuterol MDI 2

puffs given. Eight attempts were made for DLCO, none of which were acceptable.

	Pre-Bronch			Po		
	<b>Actual</b>	<u>Pred</u>	%Pred	<u>Actual</u>	%Pred	%Chng
SPIROMETRY			•			
FVC (L)	3.08	4.16	74	4.11	99	33
FEV1 (L)	1.11	3.45	32	2.42	· <b>7</b> 0	119
FEV1/FVC (%)	36	83	43	59	71	64
FEF 25% (L/sec)	1.00	7.48	13	3.14	42	212
FEF 75% (L/sec)	0.42	2.04	21	2.14	105	410
FEF 25-75% (L/sec)	0.43	3.74	11	2.15	58	405
FEF Max (L/sec)	1.12	8.91	13	3.22	36	187
FIVC (L)	2.14					
FIF Max (L/sec)	1.33					
LUNG VOLUMES						
SVC (L)	1.59	4.87	33			
IC (L)	1.02	3.32	31			•
ERV (L)	0.57	1.55	37			
FRC (N2) (L)	8.72	3.28	266			
RV (N2) (L)	8.15	1.82	448			
TLC (N2) (L)	9.74	6.72	145	•		
RV/TLC (N2) (%)	84	28	299			
Washout Time (min)	2.61					

#### **Pulmonary Function Report**


1000 Bower Hill Rd.

Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

881985 D.O.B.:07/07/1970 Date: 01/08/2007 Ward, Myron ID: Name: Height: 68.00 Room: Outpatient T. Zeman, CRT, RPsgT. Age: 36 Tech: Black Weight: 150.60 Male Race: Sex: Doctor: G. Fino, M.D.



## **Pulmonary Function Report**


1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000


Fax: 412-942-2024

					0= (0= (1.0=0	-	01/00/0007
Name	Ward, Myron	ID:	881985	D.O.B	.:07/07/1970	Date:	01/08/2007
		TT = 1 = 1 = 4 .	40 nn	Age:	36	Room:	Outpatient
Tech:	T. Zeman, CRT, RPsgT.	Height:	00.00	Age.	30	ROOM.	Outpatient
The exercise	C Eine MD	Weight:	150.60	Sex:	Male	Race:	Black
Doctor:	G. Fino, M.D.	W Cigitt.	150.00	5011.			

Time				absolute FVC absolute	FVC	absolute FEV1 absolute	FEV1	FEV1/FVC	absolute FEF 25-75% absolute
Pre									
09:49:48	*		back e	3.08	74	0.94	27	31	0.43
09:46:51	*		back e	2.88	69	1.11	32	38	0.77
09:48:29	*		back e	2.56	62	0.68	20	26	0.37
09:45:52	*		back e	1.61	39	1.03	30	64	0.45
Composite		Pre/Baseline		3.08	74	1.11	32	36	0.43
Post									
10:23:50	*		end of	4.11	+33	2.42	+119	59	2.15
10:25:13	*		back e	4.06	+32	2.34	+111	57	2.17
10:22:34	*			3.85	+25	2.35	+112	61	1.92
10:21:02	*		back e	4.11	+33	1.70	+53	41	1.25
Composite		Post		4.11	+33	2.42	+119	59	2.15









## **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024





### **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024


Name	Ward, Myron	ID:	881985	D.O.B	.:07/07/1970	Date:	01/08/2007
Tech:	T. Zeman, CRT, RPsgT.	Height:	68.00	Age:	36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	150.60	Sex:	Male	Race:	Black

Select RpLp Test Mode Codes Protocol Time

> DLCOunc DLCOcor DLCOcor DL/VA absolute % p/c absolute % p/c absolute 37.63 36.95 5.86

Predicted

Pre




## **Pulmonary Function Report**

1000 Bower Hill Rd. Pittsburgh, PA, 15243

Phone: 412-942-2000

Fax: 412-942-2024

Ward, Myron ID: 881985 D.O.B.:07/07/1970 Date: 01/08/2007 Name Height: 68.00 Age: 36 Room: Outpatient Tech: T. Zeman, CRT, RPsgT. Weight: 150.60 Sex: Black Doctor: G. Fino, M.D. Male Race:



### **Pulmonary Function Report**


1000 Bower Hill Rd.

Pittsburgh, PA, 15243

Phone: 412-942-2000 Fax: 412-942-2024

Name:	Ward, Myron	ID:	881985	D.O.B	.:07/07/1970	Date:	01/08/2007
Tech:	T. Zeman, CRT, RPsgT.	Height:	68.00	Age:	36	Room:	Outpatient
Doctor:	G. Fino, M.D.	Weight:	150.60	Sex:	Male	Race:	Black

Time	Select	RpLp	Test Mode	•			•	
	•			FRC (N2) absolute	FRC (N2) % p/c	RV (N2) absolute	RV (N2) % p/c	TLC (N2) absolute
Predicted				3.28		1.82		6.72
Pre								
10:11:26	*			8.72	266	8.15	448	9.74
AVG			Pre/Baseline	8.72	266	8.15	448	9.74
Post								



WARD, MYRON

MR#:881985 SEX:M AGE:36Y BIRTH:07/07/1970

DOCTOR: FINO, GREGORY J., M.D.

1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

ST CLAIR HOSPITAL LABORATORY

1000 BOWER HILL ROAD

PITTSBURGH, PA 15243

MARTHA R. CLARKE, MD, MEDICAL DIRECTOR

M819 COLL: 01/08/2007 11:13 REC: 01/08/2007 11:15

COMP METABOLIC			
SGOT/AST	17	[0-50]	U/L
SGPT/ALT	9	[0-50]	U/L
ALKALINE PHOSPHAT	60	[43-122]	U/L
BILIRUBIN TOTAL	0.4	[0.2-1.3]	MG/DL
PROTEIN	7.7	[6.0-8.4]	G/DL
ALBUMIN	4.6	[3.5-5.0]	G/DL
CALCIUM	9.5	[8.0-10.2]	MG/DL
GLUCOSE	86	[70-110]	MG/DL
BUN	17	[8-25]	MG/DL
CREATININE	1.1	[0.6-1.5]	MG/DL
GFR (CAUCAS/OTHER)	>59	[>59]	ML/MIN
GFR (AFRICAN AMER)	>59	[>59]	ML/MIN
SODIUM	141	[133-145]	MMOL/L
POTASSIUM	4.0	[3.5-5.0]	MMOL/L
CHLORIDE	104	[96-108]	MMOL/L
CO2	29	[22-30]	MMOL/L
ANION GAP	8	[8-16]	MMOL/L
CBC HEMOGRAM			
WBC	4.9	[4.8-10.8]	K/UL
RBC	5.09	[4.7-6.2]	M/UL
HEMOGLOBIN	15.5	[14.0-17.0]	GM/DL
HEMATOCRIT	44.2	[42.0-52.0]	& &
MCV	86.8	[78.0-94.0]	FL
MCH	30.5	[25.0-35.0]	PG
MCHC	35.1	[31.0-36.5]	G/DL
RDW	@12.7	[12.9-14.9]	8
PLATELET	197	[130-460]	ĸ/UL
MPV	@6.7	[7.4-10.4]	FL
•••		2011,	
DIFF, ELECTRONIC			
ABSOLUTE NEUTROPH	2.8	[1.5-6.6]	K/UL
ABSOLUTE LYMPHOCY	2.0	[1.5-3.5]	K/UL
ABSOLUTE MONOCYTE	0.2	[0-0.9]	K/UL
ABSOLUTE EOSINOPH	0.0	[0-0.6]	K/UL
ABSOLUTE BASOPHIL	0.0	[0-0.1]	K/UL
NEUTROPHIL	58.1	[40-75]	ક
LYMPHOCYTE	36.8	[20-40]	ક
MONOCYTE	3.8	[1-8]	ું જ
EOSINOPHIL	0.8	[0-5]	용
BASOPHIL	0.4	[0-1]	용

#### PAGE:1

FINO, GREGORY J., M.D. 1000 BOWER HILL RD. SUITE 211

PITTSBURGH PA 15243

1TIME
\* = CRITICAL VALUE

@ = OUTSIDE NORMAL RANGE

END OF REPORT

# CLINICAL & OCCUPATIONAL PULMONARY ASSOCIATES, LLC

Gregory J. Fino, MD, FCCP

St. Clair Hospital 1000 Bower Hill Road, Suite 211 Pittsburgh, Pennsylvania 15243-1899

Telephone (412) 942-2025 Fax (412) 942-2032

Email gregory.fino@stclair.org

PATIENT WARD, MYRON
DATE 1-8-01

PULSE OXIMETRY 100% on Room air CC = / ppm o. COHb